BioNexus Gene Net Worth
BioNexus Gene Net Worth Breakdown | BGLC |
BioNexus Gene Net Worth Analysis
BioNexus Gene's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including BioNexus Gene's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of BioNexus Gene's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform BioNexus Gene's net worth analysis. One common approach is to calculate BioNexus Gene's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares BioNexus Gene's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing BioNexus Gene's net worth. This approach calculates the present value of BioNexus Gene's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of BioNexus Gene's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate BioNexus Gene's net worth. This involves comparing BioNexus Gene's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into BioNexus Gene's net worth relative to its peers.
To determine if BioNexus Gene is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding BioNexus Gene's net worth research are outlined below:
| BioNexus Gene Lab is way too risky over 90 days horizon | |
| BioNexus Gene Lab appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 9.51 M. Net Loss for the year was (1.6 M) with profit before overhead, payroll, taxes, and interest of 1.27 M. | |
| BioNexus Gene Lab currently holds about 1.34 M in cash with (2.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| BioNexus Gene Lab has a very weak financial position based on the latest SEC disclosures | |
| Roughly 51.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: Apogee Therapeutics Given Buy Rating at Guggenheim |
BioNexus Gene uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in BioNexus Gene Lab. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to BioNexus Gene's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Follow BioNexus Gene's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.55 M.Project BioNexus Gene's profitablity
The company has Profit Margin (PM) of (0.23) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.27) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.27.When accessing BioNexus Gene's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures BioNexus Gene's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of BioNexus Gene's profitability and make more informed investment decisions.
Please note, the presentation of BioNexus Gene's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BioNexus Gene's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of BioNexus Gene's management manipulating its earnings.
Evaluate BioNexus Gene's management efficiency
BioNexus Gene Lab has return on total asset (ROA) of (0.1405) % which means that it has lost $0.1405 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2475) %, meaning that it created substantial loss on money invested by shareholders. BioNexus Gene's management efficiency ratios could be used to measure how well BioNexus Gene manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Net Tangible Assets is expected to grow to about 8.7 M, whereas Total Assets are forecasted to decline to about 6.7 M.The decision-making processes within BioNexus Gene are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue 0.8803 | Revenue | Quarterly Revenue Growth (0.10) | Revenue Per Share 5.178 | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioNexus Gene insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioNexus Gene's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioNexus Gene insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Wei Leong over a year ago BioNexus Gene exotic insider transaction detected |
BioNexus Gene Earnings per Share Projection vs Actual
BioNexus Gene Corporate Management
| Sook Yeoh | CEO Director | Profile | |
| Kwan Chan | Marketing Manager | Profile | |
| Too Tham | Managing Director | Profile | |
| Wei Leong | CFO Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNexus Gene Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Specialty Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNexus Gene. If investors know BioNexus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNexus Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (1.19) | Revenue Per Share 5.178 | Quarterly Revenue Growth (0.10) | Return On Assets (0.14) |
The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNexus Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNexus Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNexus Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.